Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790488 | 0.93 | CYP2D6 (0.44) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10749865 | 0.90 | CYP2D6 (0.59) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL9814120 | 0.87 | ADRA1A (0.53) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10749333 | 0.86 | CYP2D6 (0.54) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL9814124 | 0.84 | ADRA1A (0.53) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10749519 | 0.83 | CYP2D6 (0.54) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL9814102 | 0.81 | ADRA1A (0.48) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10747744 | 0.80 | CYP2D6 (0.49) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL769130 | 0.79 | ADRA1A (0.62) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Hydrochloric Acid SCHEMBL10749973 | 0.79 | CYP2D6 (0.57) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | claimed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | claimed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | claimed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | claimed |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | disclosed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-7767667-B2 | Pesticidal heterocycles | FMC CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090012070-A1 | PESTICIDAL HETEROCYCLES | BAYER CROPSCIENCE AG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-7417057-B2 | Pesticidal heterocycles | BAYER CROPSCIENCE AG (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1499609-A4 | PESTICIDAL HETEROCYCLES | FMC CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050143418-A1 | Pesticidal heterocycles | FMC CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1499609-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003092374-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, DCK, CHEK2 | ADRA1A 4261/4885ADRA2A 3804/4885CYP2D6 4634/4885 |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, CHEK2, DCK | ADRA1A 4320/4885ADRA2A 3950/4885CYP2D6 4762/4885 |
| US-20090012070-A1 | PESTICIDAL HETEROCYCLES | DDT, CBR3, ACHE | ADRA1A 1130/4885ADRA2A 1935/4885CYP2D6 1682/4885 |
| US-20050143418-A1 | Pesticidal heterocycles | DDT, TRHR, ACHE | ADRA1A 974/4885ADRA2A 1884/4885CYP2D6 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.